RBC Capital Reiterates Outperform on Korro Bio, Maintains $95 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Luca Issi has reiterated an Outperform rating on Korro Bio (NASDAQ:KRRO) and maintained a price target of $95.
September 19, 2024 | 2:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Korro Bio, maintaining a $95 price target, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and a maintained price target of $95 by RBC Capital suggests positive sentiment and confidence in Korro Bio's future performance. This is likely to have a positive short-term impact on the stock price as it reflects analyst confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100